The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1297
Certolizumab (Cimzia) for Crohn's Disease
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved the marketing of certolizumab pegol (Cimzia – UCB), a tumor necrosis factor (TNF) blocker, for treatment of moderate to severe Crohn’s disease refractory to conventional treatment. It is the third TNF blocker approved for this indication.

MECHANISM OF ACTION — Tumor necrosis factor alpha (TNFa) is a pro-inflammatory cytokine. Certolizumab is a PEGylated Fab fragment of a humanized anti-TNFa antibody. Antibodies and antibody fragments that bind TNFa block the inflammatory cascade.1 Unlike infliximab and adalimumab, certolizumab does not induce complement-activated cytotoxicity, antibodydependent T-cell mediated cytotoxicity, or apoptosis. The effect of these mechanistic differences on drug efficacy and tolerability has not been established.

CLINICAL STUDIES — In a dose-response study, 292 patients with moderate to severe Crohn's ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Certolizumab (Cimzia) for Crohn's Disease
Article code: 1297a
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian